HSV

DGAP-News: AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of HSV infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Retrieved on: 
Thursday, July 8, 2021
Chemical compounds, Purines, Organic compounds, Foscarnet, Aciclovir, Chemistry, pritelivir, HSV, AiCuris Anti-infective Cures AG, PRITELIVIR, HSV, AICURIS ANTI-INFECTIVE CURES AG

The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Key Points: 
  • The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
  • Efficacy was also seen in patients who in addition showed resistance or intolerance to foscarnet and had very limited treatment options.
  • In none of the patients, treatment with pritelivir was prematurely discontinued due to adverse events during the trial.
  • Based on the results from the recent US clinical phase 2 trial, AiCuris has started a pivotal phase 3 trial as a basis for NDA submission.

Rational Vaccines Licenses Promising Technology from Louisiana State University

Retrieved on: 
Monday, April 5, 2021
Sexually transmitted diseases and infections, Medical specialties, Herpes, Virology, Microbiology, Viral diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, Genital herpes, HSV, Vaccine

CEO says licensing of VC2 is a significant milestone for Rational Vaccines as they strive to eradicate the herpes virus.

Key Points: 
  • CEO says licensing of VC2 is a significant milestone for Rational Vaccines as they strive to eradicate the herpes virus.
  • "We are so very excited about adding this incredible science to the Rational Vaccines arsenal and partnering with Louisiana State University in the fight against HSV," said Rational CEO Agustin Fernandez.
  • The VC2 vaccines target facial, ocular and genital herpes caused by HSV-1, but may also provide protection against genital herpes causes by HSV-2.
  • Based in Cambridge, MA, Rational Vx is also joining the battle against COVID-19 with a serological assay currently in development, and a future COVID-19 vaccineplanned.

Leading Scientist Dr. Konstantin Kousoulas Shares His Mission to Eradicate Herpes

Retrieved on: 
Monday, March 1, 2021
Medical specialties, Biology of bipolar disorder, Herpes simplex, Gus Fring, HSV, Fictional characters, Clinical medicine

CAMBRIDGE, Mass., March 1, 2021 /PRNewswire/ -- By 1999 Dr. Konstantin 'Gus' Kousoulas was a tenured professor and consultant.

Key Points: 
  • CAMBRIDGE, Mass., March 1, 2021 /PRNewswire/ -- By 1999 Dr. Konstantin 'Gus' Kousoulas was a tenured professor and consultant.
  • Scientist hopes to fufill his father's challenge to do something positive for humanity and to help put an end to HSV.
  • People like you that are this smart, you should do something as opposed to just (making money)," Kousoulas said.
  • It was as a young scientist he first began to understand the impact herpes has on everyday people.

Journal of Virology publishes paper on Rational Vaccines live-attenuated vaccine candidate

Retrieved on: 
Monday, January 11, 2021
Medical specialties, Sexually transmitted diseases and infections, Microbiology, Branches of biology, Vaccination, Virology, Herpes simplex virus, Herpes simplex, Herpes simplex research, Vaccine, HSV-2, HSV

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- A study of Rational Vaccines' herpes simplex virus candidate published in the Journal of Virology demonstrates that the vaccine candidate, RVX10,offered robust protection against ocular herpes simplex virus 1 (HSV-1) infection in vaccinated mice.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- A study of Rational Vaccines' herpes simplex virus candidate published in the Journal of Virology demonstrates that the vaccine candidate, RVX10,offered robust protection against ocular herpes simplex virus 1 (HSV-1) infection in vaccinated mice.
  • This robust efficacy was found to be correlated with CD8+ T cells, since depleting these cells after vaccination, but before challenge with HSV-1 eliminated any efficacy realized by the vaccine.
  • Ocular HSV can cause disease in any layer of the eye and is mainly spread by direct contact.
  • Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, particularly focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

HSV Eraser Review: PDF eBook For Permanently Eliminate the Herpes Virus from One's Body

Retrieved on: 
Tuesday, December 29, 2020
Sexually transmitted diseases and infections, Medical specialties, Virology, Viral diseases, Herpes, Infectious diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, HSV, Herpes simplex research

Readers should know that there are two types of the herpes virus, HSV1, and HSV2.

Key Points: 
  • Readers should know that there are two types of the herpes virus, HSV1, and HSV2.
  • Now, the HSV Eraser Review is a 21-day program kit that helps in the treatment of herpes .
  • The more conventional treatment doesn't permanently wipe away the virus from the body.
  • On the other hand, HSV Eraser Reviewis a cure that will help users to get rid of the virus permanently.

HSV Eraser Review: PDF eBook For Permanently Eliminate the Herpes Virus from One's Body

Retrieved on: 
Tuesday, December 29, 2020
Sexually transmitted diseases and infections, Medical specialties, Virology, Viral diseases, Herpes, Infectious diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, HSV, Herpes simplex research

Readers should know that there are two types of the herpes virus, HSV1, and HSV2.

Key Points: 
  • Readers should know that there are two types of the herpes virus, HSV1, and HSV2.
  • Now, the HSV Eraser Review is a 21-day program kit that helps in the treatment of herpes .
  • The more conventional treatment doesn't permanently wipe away the virus from the body.
  • On the other hand, HSV Eraser Reviewis a cure that will help users to get rid of the virus permanently.

DGAP-News: AiCuris received approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Retrieved on: 
Wednesday, December 2, 2020
Medical specialties, Sexually transmitted diseases and infections, Viral diseases, Purines, Virology, Clinical medicine, Aciclovir, Herpes simplex, Expanded access, Pritelivir, HSV, Compassionate Use Program (CPU), AiCuris Anti-infective Cures GmbH

"Especially in immunocompromised patients, HSV can lead to serious complications," said Dr. Holger Zimmermann, CEO of AiCuris.

Key Points: 
  • "Especially in immunocompromised patients, HSV can lead to serious complications," said Dr. Holger Zimmermann, CEO of AiCuris.
  • At the same time, the data collected in this program will help to bring the drug to patients as quickly as possible and support the planned approval of pritelivir."
  • The Compassionate Use Program in Germany is part of an Early Access Program (EAP) which is operated by myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection.
  • The EAP for treatment of acyclovir-resistant mucocutaneous HSV infections provides immunocompromised patients in different countries worldwide with pre-approval access to pritelivir.

Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development

Retrieved on: 
Monday, July 20, 2020
Sexually transmitted diseases and infections, Medical specialties, Infectious diseases, Herpes simplex virus, HSV, Herpes simplex, Organ systems

PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created position of Senior Vice President, Strategy and Business Development.

Key Points: 
  • PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created position of Senior Vice President, Strategy and Business Development.
  • Ms. Ijem joins Krystal from Guggenheim Securities, where she served as Managing Director and Senior Biotechnology Analyst covering genetic medicine and rare disease companies.Ms.
  • We are thrilled to welcome Whitney to Krystal Biotech, said Krish S. Krishnan, chairman and chief executive officer of Krystal Biotech.
  • Whitney Ijem added, I have followed the Krystal story for years and have been encouraged by the clinical data generated so far.

DGAP-News: AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

Retrieved on: 
Friday, June 5, 2020
Viruses, RTT, Infectious diseases, Medical specialties, Sexually transmitted diseases and infections, Viral diseases, Purines, Herpes, Foscarnet, Aciclovir, Herpes simplex, Breakthrough therapy, Breakthrough Therapy Designation, Pritelivir, HSV, AiCuris Anti-infective Cures GmbH

AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

Key Points: 
  • AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
    The issuer is solely responsible for the content of this announcement.
  • AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
    Wuppertal, June 05, 2020 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the Company has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris' lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised adults.
  • foscarnet, a virostatic agent which is used mainly for the treatment of HSV resistant to other antiviral drugs.
  • With the Breakthrough Therapy designation, AiCuris reached an important milestone and is now looking for a partner for the further development of pritelivir.

Herpes Dating Site/App MPWH Sees an Over 150 Percent Increase in Traffic in Recent Two Months, Helping Make Its Members More Confident in Real Life

Retrieved on: 
Saturday, June 16, 2018
RTT, Microbiology, Biology of bipolar disorder, Herpes simplex, MPWH, Medicine, Herpes, HSV

MPWH, an online community for singles with herpes, is breaking through these obstacles, growing at a rapid rateand skyrocketing members lifestyles and self-esteem.

Key Points: 
  • MPWH, an online community for singles with herpes, is breaking through these obstacles, growing at a rapid rateand skyrocketing members lifestyles and self-esteem.
  • In news sure to be a relief for people with herpes, online herpes dating site and app MPWH is helping to remove the stigma associated with HSV.
  • In an amazing breakthrough, MPWH recently celebrated a 150 percent growth in membership in just two months, compared to the same months in 2017.
  • The value it offers to people with herpes wanting to build rebuild their social life can be immense.